Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.
Christiansen SN, Ørnbjerg LM, Rasmussen SH, Loft AG, Askling J, Iannone F, Zavada J, Michelsen B, Nissen M, Onen F, Santos MJ, Pombo-Suarez M, Relas H, Macfarlane GJ, Tomsic M, Codreanu C, Gudbjornsson B, Van der Horst-Bruinsma I, Di Giuseppe D, Glintborg B, Gremese E, Pavelka K, Kristianslund EK, Ciurea A, Akkoc N, Barcelos A, Sánchez-Piedra C, Peltomaa R, Jones GT, Rotar Z, Ionescu R, Grondal G, Van de Sande MGH, Laas K, Østergaard M, Hetland ML. Christiansen SN, et al. Among authors: tomsic m. Rheumatology (Oxford). 2022 Aug 30;61(9):3799-3807. doi: 10.1093/rheumatology/keab945. Rheumatology (Oxford). 2022. PMID: 34940840
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF. Chatzidionysiou K, et al. Among authors: tomsic m. Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12. Ann Rheum Dis. 2011. PMID: 21571731
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF, Gabay C. Chatzidionysiou K, et al. Among authors: tomsic m. Ann Rheum Dis. 2012 Mar;71(3):374-7. doi: 10.1136/annrheumdis-2011-200003. Epub 2011 Oct 4. Ann Rheum Dis. 2012. PMID: 21972242
Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry.
Perdan-Pirkmajer K, Hočevar A, Rotar Ž, Žibert J, Marolt VF, Gučev F, Tomšič M. Perdan-Pirkmajer K, et al. Among authors: tomsic m. Rheumatol Int. 2013 Nov;33(11):2885-8. doi: 10.1007/s00296-012-2524-z. Epub 2012 Sep 7. Rheumatol Int. 2013. PMID: 22955878
Incidence of scleroderma spectrum disorders in Slovenia.
Sipek Dolničar A, Rotar Z, Tomsič M. Sipek Dolničar A, et al. Among authors: tomsic m. Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):8-11. Epub 2012 Nov 28. Clin Exp Rheumatol. 2013. PMID: 23190708
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Walker UA, Jaeger VK, Chatzidionysiou K, Hetland ML, Hauge EM, Pavelka K, Nordström DC, Canhão H, Tomšič M, van Vollenhoven R, Gabay C. Walker UA, et al. Among authors: tomsic m. Rheumatology (Oxford). 2016 Feb;55(2):230-6. doi: 10.1093/rheumatology/kev297. Epub 2015 Aug 27. Rheumatology (Oxford). 2016. PMID: 26316581
258 results